{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:29:15Z","timestamp":1769869755355,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[1998,1]]},"DOI":"10.1016\/s1367-5931(98)80129-4","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T17:38:09Z","timestamp":1032284289000},"page":"519-528","source":"Crossref","is-referenced-by-count":176,"title":["Antisense therapeutics"],"prefix":"10.1016","volume":"2","author":[{"given":"Sudhir","family":"Agrawal","sequence":"first","affiliation":[]},{"given":"Qiuyan","family":"Zhao","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1367-5931(98)80129-4_BIB1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0167-7799(96)10053-6","article-title":"Antisense oligonucleotides: towards clinical trials","volume":"14","author":"Agrawal","year":"1996","journal-title":"Trends Biotechnol"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0165-6147(96)01002-4","article-title":"In vivo studies with antisense oligonucleotide","volume":"18","author":"Akhtar","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-2952(97)00214-1","article-title":"Antisense oligonucleotides: is the glass half full or half empty? (of special interest)","volume":"55","author":"Bennett","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB4","author":"Agrawal","year":"1996"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB5","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB6","author":"Wickstrom","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB7","year":"1997"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB8","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1073\/pnas.95.1.195","article-title":"Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage (of special interest)","volume":"95","author":"Chen","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB10","first-page":"39","article-title":"A good antisense molecule is hard to find","volume":"23","author":"Branch","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/oli.1.1997.7.245","article-title":"In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines","volume":"7","author":"Agrawal","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB12","first-page":"1313","article-title":"Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys","volume":"278","author":"Phillips","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/oli.1.1998.8.43","article-title":"Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in Cynomolgus Monkeys following intravenous infusion","volume":"8","author":"Grindel","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB14","first-page":"387","article-title":"Early clinical trials with GEM91, a systemic oligodeoxynucleotide","author":"Martin","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB15","first-page":"1173","article-title":"Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)","volume":"282","author":"Glover","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB16","first-page":"141","article-title":"Pharmacokinetic properties of phosphorothioates in animals- absorption, distribution, metabolism and elimination","author":"Nicklin","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB17","first-page":"525","article-title":"Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administration in experimental animals","author":"Agrawal","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/oli.1.1997.7.159","article-title":"In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide","volume":"7","author":"Temsamani","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB19","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0960-894X(97)00201-1","article-title":"Phosphorothioate oligonucleotide metabolism: characterization of the \u2018N+\u2019- mer by CE and HPLC-ES\/MS","volume":"7","author":"Cummins","year":"1997","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB20","first-page":"379","article-title":"Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues (of special interest)","volume":"77","author":"Butler","year":"1997","journal-title":"Lab Invest"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000189504","article-title":"Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo","volume":"75","author":"Carome","year":"1997","journal-title":"Nephron"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB22","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1093\/nar\/25.16.3290","article-title":"In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells","volume":"25","author":"Bijsterbosch","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB23","doi-asserted-by":"crossref","DOI":"10.1089\/oli.1.1998.8.451","article-title":"Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice","author":"Zhao","year":"1998","journal-title":"Antisense Nucl Acid Drug Dev"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/oli.1.1997.7.575","article-title":"Toxicological Effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats","volume":"7","author":"Agrawal","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB25","first-page":"395","article-title":"Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides","volume":"12","author":"Henry","year":"1997","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0300-483X(97)03661-5","article-title":"Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys","volume":"120","author":"Henry","year":"1997","journal-title":"Toxicology"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB27","first-page":"169","article-title":"Toxicity of oligonucleotide therapeutic agents","author":"Levin","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/oli.1.1998.8.135","article-title":"Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo (of special interest)","volume":"8","author":"Agrawal","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB29","first-page":"233","article-title":"Safety and tolerance of phosphorothioate in humans","author":"Schechter","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB30","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/0006-2952(93)90014-N","article-title":"Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1","volume":"45","author":"Branda","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB31","first-page":"431","article-title":"Leukocyte stimulation by oligodeoxynucleotides (of special interest)","author":"Krieg","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0006-2952(95)02177-9","article-title":"Effect of different chemical modified oligodeoxynucleotides on immune stimulation","volume":"51","author":"Zhao","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB33","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1073\/pnas.93.7.2879","article-title":"CpG motifs expressed by bacterial DNA rapidly induced lymphocytes to secrete IL-6, IL-12 and IFN-\u03b3","volume":"93","author":"Klinman","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/oli.1.1997.7.495","article-title":"Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice (of special interest)","volume":"7","author":"Zhao","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(00)80256-3","article-title":"Immune activation by bacterial DNA: a new genetic code","volume":"5","author":"Pisetsky","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB36","first-page":"619","article-title":"Interleukin-12:biological activity, therapeutic utility, and role in disease","volume":"72","author":"Hendrzak","year":"1995","journal-title":"Lab Invest"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB37","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.4049\/jimmunol.156.10.3583","article-title":"\u2018The good, the bad, and the ugly\u2019 The role of chemokines in models of human disease","volume":"156","author":"Strieter","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB38","first-page":"224","article-title":"Oligonucleotide as antiviral agents","author":"Agrawal","year":"1997"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB39","first-page":"353","article-title":"Treatment of retinitis induced by cytomegalovirus using intravitral formivirsen (ISIS 2922)","author":"Crooke","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1472-8206.1996.tb00153.x","article-title":"Recent status of the antisense oligonucleotide approaches in oncology","volume":"10","author":"F Calvo","year":"1996","journal-title":"Fundam Clin Pharmcol"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB41","first-page":"373","article-title":"Targeting c-myc in leukemia","volume":"12","author":"Calabretta","year":"1997","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00062752-199801000-00011","article-title":"Antisense oligonucleotide therapeutics for human leukemia","volume":"5","author":"Gewirtz","year":"1998","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB43","first-page":"327","article-title":"First- and second-generation antisense inhibitors targeted to human c-raf kinase, in vitro and in vivo studies","volume":"12","author":"Monia","year":"1997","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB44","first-page":"35","article-title":"Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice","volume":"13","author":"Geiger","year":"1998","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB45","doi-asserted-by":"crossref","first-page":"12586","DOI":"10.1073\/pnas.94.23.12586","article-title":"Synergistric inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A","volume":"94","author":"Tortora","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB46","first-page":"359","article-title":"In vitro and in vivo activity of antisense inhibitiors of ras: potential for clinical development","volume":"12","author":"Cowsert","year":"1997","journal-title":"Anticancer Drug Design"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB47","first-page":"169","article-title":"Human bcl-2 antisense therapy for lymphomas","author":"Cotter","year":"1998"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0166-3542(98)00004-7","article-title":"Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors","volume":"38","author":"Veal","year":"1998","journal-title":"Antiviral Res"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB49","first-page":"283","article-title":"c-Myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice","volume":"58","author":"Citro","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB50","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and transformation by a specific oligonucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB51","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.onc.1201646","article-title":"High prognostic significance of mdm2\/p53 co-overexpression in soft tissue sarcomas of the extremities","volume":"16","author":"Wurl","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/S1367-5931(98)80129-4_BIB52","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V84.9.3158.3158","article-title":"The mdm2 oncogene over-expression in chronic lymphocytic leukemia and low grade lymphoma of B cell origin","volume":"84","author":"Watanabe","year":"1994","journal-title":"Blood"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593198801294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593198801294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T16:21:50Z","timestamp":1682353310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593198801294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["S1367593198801294"],"URL":"https:\/\/doi.org\/10.1016\/s1367-5931(98)80129-4","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[1998,1]]}}}